AU2014364962B2 - Oral formulations of pyrrolidine derivatives - Google Patents

Oral formulations of pyrrolidine derivatives Download PDF

Info

Publication number
AU2014364962B2
AU2014364962B2 AU2014364962A AU2014364962A AU2014364962B2 AU 2014364962 B2 AU2014364962 B2 AU 2014364962B2 AU 2014364962 A AU2014364962 A AU 2014364962A AU 2014364962 A AU2014364962 A AU 2014364962A AU 2014364962 B2 AU2014364962 B2 AU 2014364962B2
Authority
AU
Australia
Prior art keywords
dispersible tablet
carbonyl
methyl
biphenyl
hydroxymethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014364962A
Other languages
English (en)
Other versions
AU2014364962A1 (en
Inventor
Andre Chollet
Olivier POHL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Obseva SA
Original Assignee
Obseva SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Obseva SA filed Critical Obseva SA
Publication of AU2014364962A1 publication Critical patent/AU2014364962A1/en
Application granted granted Critical
Publication of AU2014364962B2 publication Critical patent/AU2014364962B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
AU2014364962A 2013-12-17 2014-12-15 Oral formulations of pyrrolidine derivatives Active AU2014364962B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13197606.0 2013-12-17
EP13197606.0A EP2886107A1 (en) 2013-12-17 2013-12-17 Oral formulations of pyrrolydine derivatives
PCT/EP2014/077767 WO2015091365A1 (en) 2013-12-17 2014-12-15 Oral formulations of pyrrolidine derivatives

Publications (2)

Publication Number Publication Date
AU2014364962A1 AU2014364962A1 (en) 2016-07-28
AU2014364962B2 true AU2014364962B2 (en) 2020-03-26

Family

ID=49765403

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014364962A Active AU2014364962B2 (en) 2013-12-17 2014-12-15 Oral formulations of pyrrolidine derivatives

Country Status (19)

Country Link
US (5) US20170065556A1 (OSRAM)
EP (4) EP2886107A1 (OSRAM)
JP (2) JP6479800B2 (OSRAM)
KR (1) KR102350156B1 (OSRAM)
CN (2) CN110960495B (OSRAM)
AU (1) AU2014364962B2 (OSRAM)
CA (1) CA2931592C (OSRAM)
CY (1) CY1119728T1 (OSRAM)
DK (1) DK3082773T3 (OSRAM)
EA (2) EA031530B1 (OSRAM)
ES (2) ES2654927T3 (OSRAM)
HK (1) HK1249050B (OSRAM)
HU (1) HUE035212T2 (OSRAM)
IL (2) IL245855B (OSRAM)
MX (2) MX363697B (OSRAM)
PT (1) PT3082773T (OSRAM)
SI (1) SI3082773T1 (OSRAM)
UA (1) UA116824C2 (OSRAM)
WO (1) WO2015091365A1 (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2845850A1 (en) 2013-09-10 2015-03-11 ObsEva S.A. Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists
EP2886107A1 (en) * 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
EP3753921A1 (en) 2014-07-02 2020-12-23 ObsEva S.A. Crystalline (3z,5s)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one o-methyloxime useful in methods of treating conditions related to the ot-r activity
TWI829098B (zh) 2015-01-02 2024-01-11 美商梅拉洛伊卡公司 細菌組成物
ES2915948T3 (es) 2016-01-04 2022-06-27 ObsEva SA Administración conjunta de alfa-aminoéster de derivado de hidroxipropiltiazolidin-carboxamida y un agente tocolítico
WO2018015497A2 (en) * 2016-07-21 2018-01-25 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
IT201600101413A1 (it) 2016-10-10 2018-04-10 Sofar Swiss S A Composizione liquida per uso nel trattamento del reflusso gastroesofageo
IT201700124434A1 (it) * 2017-10-31 2019-05-01 Sofar Swiss Sa Compressa da succhiare e/o sciogliere in bocca a base di acido ialuronico e condroitina solfato e loro sali per uso nel trattamento di una sottopopolazione di pazienti GERD.
IT201700124424A1 (it) 2017-10-31 2019-05-01 Sofar Swiss Sa Compressa da succhiare e/o sciogliere in bocca a base di acido ialuronico e condroitina solfato e loro sali
GB201910125D0 (en) * 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of angioedema
GB201910116D0 (en) * 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of hereditary angioedema
EP4025207A1 (en) * 2019-09-03 2022-07-13 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
AU2021218895A1 (en) 2020-02-10 2022-09-15 ObsEva S.A. Biomarkers for oxytocin receptor antagonist therapy
SMT202200411T1 (it) 2020-05-18 2022-11-18 Orexo Ab Nuova composizione farmaceutica per il rilascio controllato di farmaci
AU2022395920A1 (en) 2021-11-25 2024-05-30 Orexo Ab Pharmaceutical composition comprising adrenaline
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002074741A1 (en) * 2001-03-20 2002-09-26 Applied Research Systems Ars Holding Nv Pyrrolidine ester derivatives with oxytocin modulating acitvity
WO2004005249A1 (en) * 2002-07-05 2004-01-15 Applied Research Systems Ars Holding N.V. Pyrrolidine derivatives as oxytocin antagonists
WO2004076407A2 (en) * 2003-02-27 2004-09-10 Applied Research Systems Ars Holding N.V. Pyrrolidine derivatives as oxytocin antagonists

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3482815A (en) 1967-07-07 1969-12-09 Victor Naturale Collapsible core for a mold
YU120988A (en) * 1988-06-23 1990-06-30 Lek Tovarna Farmacevtskih Process for preparing new dispersion pills of cimetidine
US4832307A (en) 1988-09-15 1989-05-23 Toshiba Kikai Kabushiki Kaisha Injection mold
YU183988A (en) * 1988-09-30 1990-08-31 Lek Tovarna Farmacevtskih Process for preparing dispersion pills of dihydroergotoxine
US5089043A (en) 1989-11-09 1992-02-18 Shionogi & Co., Ltd. Heterocyclic oxy-phenoxyacetic acid derivatives and their use as herbicides
US5889001A (en) 1993-07-29 1999-03-30 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
JP2869854B2 (ja) 1994-10-19 1999-03-10 株式会社トスカ 合成樹脂の成形方法とその装置
JP3534903B2 (ja) 1995-06-09 2004-06-07 鐘淵化学工業株式会社 １−［３−クロロ−（２ｓ）−メチルプロピオニル］−ピロリジン−（２ｓ）−カルボン酸の製造方法
GB9603699D0 (en) * 1996-02-21 1996-04-17 Boots Co Plc Therapeutic composition
US6696484B2 (en) * 1997-10-31 2004-02-24 University Of Chicago Office Of Technology And Intellectual Property Method and compositions for regulation of 5-alpha reductase activity
US6329418B1 (en) 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE60027761T2 (de) * 1999-12-09 2007-01-25 Reckitt Benckiser Healthcare (Uk) Ltd., Slough Komprimierte zubereitung enthaltend nichtsteroidale entzündungshemmer
ES2261404T3 (es) 2000-03-27 2006-11-16 Applied Research Systems Ars Holding N.V. Derivados de pirrolidina utiles como inhibidores de bax.
DK1268418T3 (da) 2000-03-27 2006-09-25 Applied Research Systems Farmaceutisk aktive pyrrolidinderivater som Bax-inhibitorer
EP1444225B1 (en) 2001-06-18 2012-10-10 Merck Serono SA Pyrrolidine oxadiazole- and thiadiazole oxime derivatives being oxytocin receptor antagonists.
JP2003192582A (ja) * 2001-12-12 2003-07-09 Merck Patent Gmbh ナプロキセンナトリウムを含む速放性錠剤
EA011026B1 (ru) 2004-02-26 2008-12-30 Лаборатуар Сероно Са Способ получения пирролидиноксимов
GB2411355B (en) * 2004-02-27 2006-02-22 Niche Generics Ltd Pharmaceutical composition
KR100985449B1 (ko) * 2005-05-10 2010-10-05 페링 인터내셔널 센터 에스 에이 옥시톡신 및/또는 바소프레신 길항제의 용도
WO2007052289A2 (en) * 2005-07-22 2007-05-10 Rubicon Research Pvt Ltd. Novel dispersible tablet composition
EP1978939A2 (en) * 2005-12-27 2008-10-15 Jubilant Organosys Limited Mouth dissolving pharmaceutical composition and process for preparing the same using a high amount of silicon dioxine
JP2008189732A (ja) 2007-02-01 2008-08-21 Fujifilm Corp セルロースアシレート組成物、セルロースアシレートフィルム、光学補償シート、偏光板および液晶表示装置
US20090152770A1 (en) 2007-08-07 2009-06-18 Canon Virginia Inc. Mechanically collapsible core for injection molding
PT2572705T (pt) * 2007-10-01 2017-11-08 Lesvi Laboratorios Sl Comprimidos orodispersíveis
US9201077B2 (en) 2009-07-27 2015-12-01 Colorado State University Research Foundation Direct enzyme immunoassay for measurement of serum progesterone levels
HK1213454A1 (zh) 2012-11-26 2016-07-08 Ferring B.V. 使用图像分析诊断子宫收缩水平的方法和系统
JP5942815B2 (ja) 2012-11-26 2016-06-29 株式会社ジェイテクト 等速ジョイント用ブーツの成形金型
EP2845850A1 (en) 2013-09-10 2015-03-11 ObsEva S.A. Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists
EP2886107A1 (en) * 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
EP3753921A1 (en) 2014-07-02 2020-12-23 ObsEva S.A. Crystalline (3z,5s)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one o-methyloxime useful in methods of treating conditions related to the ot-r activity
PL3037101T3 (pl) 2014-12-22 2019-06-28 Ferring B.V. Terapia antagonistą receptora oksytocyny w fazie lutealnej w celu implantacji i uzyskania ciąży u kobiet poddawanych technikom wspomaganego rozrodu

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002074741A1 (en) * 2001-03-20 2002-09-26 Applied Research Systems Ars Holding Nv Pyrrolidine ester derivatives with oxytocin modulating acitvity
WO2004005249A1 (en) * 2002-07-05 2004-01-15 Applied Research Systems Ars Holding N.V. Pyrrolidine derivatives as oxytocin antagonists
WO2004076407A2 (en) * 2003-02-27 2004-09-10 Applied Research Systems Ars Holding N.V. Pyrrolidine derivatives as oxytocin antagonists

Also Published As

Publication number Publication date
IL245855A0 (en) 2016-07-31
KR102350156B1 (ko) 2022-01-11
CA2931592C (en) 2021-12-07
MX363697B (es) 2019-03-29
CN110960495A (zh) 2020-04-07
US20170065556A1 (en) 2017-03-09
HUE035212T2 (en) 2018-05-02
US20150164859A1 (en) 2015-06-18
EA201892033A2 (ru) 2019-02-28
JP2016540758A (ja) 2016-12-28
US9962367B2 (en) 2018-05-08
JP2019108336A (ja) 2019-07-04
EA201892033A3 (ru) 2019-03-29
US10478420B2 (en) 2019-11-19
CN110960495B (zh) 2022-05-10
EP3266449A1 (en) 2018-01-10
HK1249050B (en) 2020-01-17
CN106029057A (zh) 2016-10-12
US11419851B2 (en) 2022-08-23
WO2015091365A1 (en) 2015-06-25
IL245855B (en) 2019-02-28
SI3082773T1 (en) 2018-02-28
ES2726730T3 (es) 2019-10-08
EP3494967A1 (en) 2019-06-12
EA201691061A1 (ru) 2016-11-30
EP2886107A1 (en) 2015-06-24
EP3082773B1 (en) 2017-10-04
JP6479800B2 (ja) 2019-03-06
ES2654927T3 (es) 2018-02-15
MX2016007930A (es) 2016-09-19
AU2014364962A1 (en) 2016-07-28
MX2019003598A (es) 2019-07-15
EA031530B1 (ru) 2019-01-31
IL264259A (en) 2019-02-28
CY1119728T1 (el) 2018-06-27
DK3082773T3 (en) 2018-01-08
US20180311211A1 (en) 2018-11-01
US20230226021A1 (en) 2023-07-20
UA116824C2 (uk) 2018-05-10
PT3082773T (pt) 2018-01-09
US20200281892A1 (en) 2020-09-10
KR20160097359A (ko) 2016-08-17
CN106029057B (zh) 2019-09-03
CA2931592A1 (en) 2015-06-25
EP3082773A1 (en) 2016-10-26
EP3266449B1 (en) 2019-02-27

Similar Documents

Publication Publication Date Title
US20230226021A1 (en) Oral formulations of pyrrolidine derivatives
HK1249050A1 (en) Oral formulations of pyrrolidine derivatives
US20230097933A1 (en) Pyrrolidine derivatives as oxytocin/vasopressin v1a receptors antagonists
JP2025013885A (ja) Ｏｔ－ｒ活性に関する疾患を治療するための方法に有用な結晶質の（３ｚ，５ｓ）－５－（ヒドロキシメチル）－１－［（２’－メチル－１，１’－ビフェニル－４－イル）カルボニル］ピロリジン－３－オン о－メチルオキシム
HK40010092A (en) Oral formulations of pyrrolidine derivatives
HK1228771B (en) Oral formulations of pyrrolidine derivatives
HK1228771A1 (en) Oral formulations of pyrrolidine derivatives
BR112016013816B1 (pt) Comprimido dispersível, processo para a preparação de um comprimido dispersível e kit
HK40086793A (en) Pyrrolidine derivatives as oxytocin/vasopressin v1a receptors antagonists

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
GM Mortgages registered

Name of requester: OXFORD FINANCE LLC